With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

The voicemail — which sounds something like an automated message — begins, “This is a critical voter alert for residents of ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

Family members of a former girlfriend of B City Council Ward 5 candidate Mike Madrigal are calling for him to drop out of the ...

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) and keeping the price ...

Run it back... The post Vanderpump Rules OG Peter Madrigal Wants Reboot: ‘Let’s Do It’ appeared first on Reality Tea.